Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 May;102(5):806-808.
doi: 10.3324/haematol.2017.165266.

Better acute graft- versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Mahasweta Gooptu  1 , John Koreth  2
Affiliations
Editorial

Better acute graft- versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect?

Mahasweta Gooptu et al. Haematologica. 2017 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival. (A) Adjusted probability of overall survival following a diagnosis of grade II–IV acute GvHD among patients treated with tacrolimus-based GvHD prophylaxis. (B) Adjusted probability of overall survival following a diagnosis of grade II–IV acute GvHD among patients treated with cyclosporine-based GvHD prophylaxis. (Figure adapted from original article)
See this image and copyright information in PMC

Comment on

  • Improved survival after acute graft-versus-host disease diagnosis in the modern era.
    Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J. Khoury HJ, et al. Haematologica. 2017 May;102(5):958-966. doi: 10.3324/haematol.2016.156356. Epub 2017 Mar 16. Haematologica. 2017. PMID: 28302712 Free PMC article.

References

    1. Jagasia M, Arora M, Flowers MED, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296–307. - PMC - PubMed
    1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic cell transplantation. N Engl J Med. 2010;363(22):2091–2101. - PMC - PubMed
    1. Hahn T, McCarthy PL, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31(19):2437–2449. - PMC - PubMed
    1. Bolaños-Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014;124(22):3221–3227; quiz 3335. - PMC - PubMed
    1. Khoury HJ, Wang T, Hemmer MT, et al. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017;102(5):958–963. - PMC - PubMed

LinkOut - more resources